Annexon outlines 2026 milestones: GBS MAA filed, GA Phase 3 data H2 2026, oral C1 inhibitor data expected

Annexon, Inc.

Tanruprubart MAA filed in Europe for Guillain-Barré syndrome; U.S. BLA submission with FORWARD data planned in 2026.
Vonaprument Phase 3 ARCHER II topline data for geographic atrophy expected second half of 2026; enrolled 659 patients.
ANX1502 proof-of-concept data in cold agglutinin disease (CAD) anticipated in 2026; oral C1 inhibitor.
Financial position funds operations into late 2027, well past anticipated key milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.